JP7834711B2 - Ｂ細胞悪性腫瘍の治療 - Google Patents

Ｂ細胞悪性腫瘍の治療

Info

Publication number
JP7834711B2
JP7834711B2 JP2023507275A JP2023507275A JP7834711B2 JP 7834711 B2 JP7834711 B2 JP 7834711B2 JP 2023507275 A JP2023507275 A JP 2023507275A JP 2023507275 A JP2023507275 A JP 2023507275A JP 7834711 B2 JP7834711 B2 JP 7834711B2
Authority
JP
Japan
Prior art keywords
use according
baffr antibody
administered
cell
baffr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023507275A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023536596A (ja
JP2023536596A5 (cg-RX-API-DMAC10.html
Inventor
ハッソウナ，ナディア
チョードリー，アンウェシャ
チョードリー，ソメシュ
ウー，ジャンギー
アンジュ プンジャビ クンダマル，ニコル
Original Assignee
ノバルティス アーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノバルティス アーゲー filed Critical ノバルティス アーゲー
Publication of JP2023536596A publication Critical patent/JP2023536596A/ja
Publication of JP2023536596A5 publication Critical patent/JP2023536596A5/ja
Application granted granted Critical
Publication of JP7834711B2 publication Critical patent/JP7834711B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Seeds, Soups, And Other Foods (AREA)
JP2023507275A 2020-08-04 2021-08-02 Ｂ細胞悪性腫瘍の治療 Active JP7834711B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202063060786P 2020-08-04 2020-08-04
US63/060,786 2020-08-04
US202063114363P 2020-11-16 2020-11-16
US63/114,363 2020-11-16
US202163147507P 2021-02-09 2021-02-09
US63/147,507 2021-02-09
PCT/US2021/044113 WO2022031567A1 (en) 2020-08-04 2021-08-02 Treatment of b cell malignancies

Publications (3)

Publication Number Publication Date
JP2023536596A JP2023536596A (ja) 2023-08-28
JP2023536596A5 JP2023536596A5 (cg-RX-API-DMAC10.html) 2024-08-13
JP7834711B2 true JP7834711B2 (ja) 2026-03-24

Family

ID=77448106

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023507275A Active JP7834711B2 (ja) 2020-08-04 2021-08-02 Ｂ細胞悪性腫瘍の治療

Country Status (10)

Country Link
US (1) US20230279132A1 (cg-RX-API-DMAC10.html)
EP (1) EP4192869A1 (cg-RX-API-DMAC10.html)
JP (1) JP7834711B2 (cg-RX-API-DMAC10.html)
KR (1) KR20230042594A (cg-RX-API-DMAC10.html)
CN (1) CN116133687A (cg-RX-API-DMAC10.html)
AU (1) AU2021320129B2 (cg-RX-API-DMAC10.html)
CA (1) CA3190678A1 (cg-RX-API-DMAC10.html)
IL (1) IL300086A (cg-RX-API-DMAC10.html)
TW (1) TW202221033A (cg-RX-API-DMAC10.html)
WO (1) WO2022031567A1 (cg-RX-API-DMAC10.html)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015521593A (ja) 2012-06-12 2015-07-30 ノバルティス アーゲー 抗体製剤

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA83458C2 (uk) * 2000-09-18 2008-07-25 Байоджен Айдек Ма Інк. Виділений поліпептид baff-r (рецептор фактора активації в-клітин сімейства tnf)
AU2009272771B2 (en) 2008-07-17 2012-09-20 Novartis Ag Compositions and methods of use for therapeutic antibodies
WO2012076670A2 (en) 2010-12-10 2012-06-14 Novartis Ag Antibody formulation
US11136405B2 (en) * 2016-06-06 2021-10-05 Board Of Regents, The Unviersity Of Texas System BAFF-R antibodies and uses thereof
CA3160207A1 (en) * 2019-11-06 2021-05-14 Novartis Ag Treatment for sjogren's syndrome

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015521593A (ja) 2012-06-12 2015-07-30 ノバルティス アーゲー 抗体製剤

Also Published As

Publication number Publication date
JP2023536596A (ja) 2023-08-28
AU2021320129B2 (en) 2025-12-18
KR20230042594A (ko) 2023-03-28
WO2022031567A1 (en) 2022-02-10
US20230279132A1 (en) 2023-09-07
AU2021320129A1 (en) 2023-03-16
CA3190678A1 (en) 2022-02-10
TW202221033A (zh) 2022-06-01
CN116133687A (zh) 2023-05-16
EP4192869A1 (en) 2023-06-14
IL300086A (en) 2023-03-01

Similar Documents

Publication Publication Date Title
TWI670062B (zh) 包含抗－ｃｄ３８抗體及雷那度胺（ｌｅｎａｌｉｄｏｍｉｄｅ）之組合物
CN113613674B (zh) 治疗小细胞肺癌的联用药物组合物
CN110869765A (zh) 组合疗法
KR20250065936A (ko) 면역 체크포인트 억제제를 사용하여 암을 치료하는 방법
JP2023502585A (ja) 癌の治療のための、ＰＤ－１、ＴＧＦβ、及びＴＩＧＩＴの組み合わせ阻害
US20230398229A1 (en) Antibody drug conjugates comprising sting agonists, combinations and methods of use
TW202332699A (zh) 靶向５ｔ４之抗體及其用途
CN104822703A (zh) Igf1r和pi3k的抑制剂的组合疗法
EP4512421A1 (en) Drug combination of anti-tim-3 antibody and anti-pd-1 antibody
CN118267469A (zh) 治疗驱动基因阳性肺癌的联用药物组合物
CN111629731A (zh) 治疗癌症的组合物和方法
CN113939315B (zh) 治疗黑色素瘤的联用药物组合物
TW202502813A (zh) 包含偶聯物的藥物組合的治療方法和用途
AU2021320129B2 (en) Treatment of B cell malignancies
CN119677533A (zh) 用于治疗癌症的检查点抑制剂与溶瘤病毒的组合
AU2021320130B2 (en) Treatment of CLL
TW202517679A (zh) 以抗ｉｌｔ２抗體治療癌症
JP2025160816A (ja) 古典的ホジキンリンパ腫に対する併用療法
CN120346313A (zh) 治疗肿瘤的药物组合
CN118451108A (zh) 用抗pd-1抗体和抗cd30抗体-药物缀合物的组合治疗癌症的方法
HK1172823A (en) Cd40 antibody formulation and methods

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240802

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240802

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250729

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251016

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251218

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20251222

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260303

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260311

R150 Certificate of patent or registration of utility model

Ref document number: 7834711

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150